Collectively, these results suggest that targeting PLD1 overcome chemoradiotherapeutic resistance and PLD1 inhibitor might provide the basis for therapeutic combinations with improved clinical efficacy of HDAC inhibitor in GBM. This evidence concerns the gene HDAC9 and glioblastoma.